Biotech · Public company · Cambridge, MA, US

Beam Therapeutics Inc.

Ticker BEAM · SEC CIK 0001745999

Track this companyFree. Adds Beam Therapeutics Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials77 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

BEAM-101Phase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
BEAM-201Phase 2 · Lymphoblastic LymphomaClinicalTrials.gov · fetched Nov 12, 2026
BEAM-301: Single dose of BEAM-301 administered by IVPhase 2 · Glycogen Storage Disease Type IaClinicalTrials.gov · fetched Nov 12, 2026
BEAM-302Phase 2 · Alpha 1-Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
Long-Term Follow-up Study of patients who received BEAM-101HemoglobinopathyClinicalTrials.gov · fetched Nov 12, 2026

A Long-term Follow-up Study in Patients Who Received BEAM-101RECRUITING · started Dec 15, 2025ClinicalTrials.gov NCT07373639 · fetched Nov 12, 2026
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or LymphomaPHASE1 · RECRUITING · started Apr 29, 2025ClinicalTrials.gov NCT06934382 · fetched Nov 12, 2026
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)PHASE1_PHASE2 · RECRUITING · started Dec 6, 2024ClinicalTrials.gov NCT06735755 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)PHASE1_PHASE2 · RECRUITING · started Jun 19, 2024ClinicalTrials.gov NCT06389877 · fetched Nov 12, 2026
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 25, 2023ClinicalTrials.gov NCT05885464 · fetched Nov 12, 2026
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)RECRUITING · started Apr 1, 2023ClinicalTrials.gov NCT06071377 · fetched Nov 12, 2026
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell DiseasePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 30, 2022ClinicalTrials.gov NCT05456880 · fetched Nov 12, 2026